Wedbush Has Positive Outlook for Nuvation Bio Q3 Earnings

Nuvation Bio Inc. (NYSE:NUVB - Free Report) - Wedbush raised their Q3 2025 earnings per share (EPS) estimates for Nuvation Bio in a note issued to investors on Wednesday, May 7th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of ($0.18) for the quarter, up from their prior forecast of ($0.20). Wedbush has a "Outperform" rating and a $5.00 price objective on the stock. The consensus estimate for Nuvation Bio's current full-year earnings is ($0.36) per share. Wedbush also issued estimates for Nuvation Bio's Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.69) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.19) EPS, Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at ($0.41) EPS and FY2028 earnings at ($0.05) EPS.

Nuvation Bio (NYSE:NUVB - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.16). The company had revenue of $3.08 million during the quarter, compared to analysts' expectations of $0.42 million.

Several other equities research analysts also recently weighed in on NUVB. JMP Securities began coverage on Nuvation Bio in a report on Wednesday, April 23rd. They issued a "market outperform" rating and a $6.00 price target for the company. Citizens Jmp initiated coverage on Nuvation Bio in a research note on Wednesday, April 23rd. They issued a "mkt outperform" rating and a $6.00 price objective for the company. Citigroup initiated coverage on Nuvation Bio in a research report on Wednesday, April 23rd. They set an "outperform" rating on the stock. Jones Trading initiated coverage on Nuvation Bio in a report on Wednesday, March 12th. They set a "buy" rating and a $10.00 target price on the stock. Finally, HC Wainwright decreased their price target on Nuvation Bio from $11.00 to $10.00 and set a "buy" rating for the company in a report on Monday, March 10th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Nuvation Bio has a consensus rating of "Buy" and an average target price of $7.83.

Nuvation Bio Stock Up 1.9%

Shares of NYSE NUVB traded up $0.04 during trading hours on Monday, hitting $2.19. 2,635,959 shares of the stock were exchanged, compared to its average volume of 2,203,874. Nuvation Bio has a 12 month low of $1.54 and a 12 month high of $3.97. The firm has a fifty day moving average price of $1.99 and a 200-day moving average price of $2.36. The company has a market cap of $741.71 million, a PE ratio of -1.01 and a beta of 1.42.

Insider Activity

In other Nuvation Bio news, insider Dongfang Liu sold 20,000 shares of Nuvation Bio stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $2.50, for a total transaction of $50,000.00. Following the completion of the sale, the insider now directly owns 12,000 shares of the company's stock, valued at $30,000. The trade was a 62.50% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO David Hung bought 300,000 shares of Nuvation Bio stock in a transaction dated Monday, April 7th. The stock was purchased at an average cost of $1.62 per share, with a total value of $486,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 58,781,054 shares in the company, valued at approximately $95,225,307.48. The trade was a 0.51% increase in their position. The disclosure for this purchase can be found here. Company insiders own 29.93% of the company's stock.

Institutional Investors Weigh In On Nuvation Bio

A number of institutional investors have recently added to or reduced their stakes in the business. Algert Global LLC increased its holdings in Nuvation Bio by 15.3% during the 1st quarter. Algert Global LLC now owns 1,005,226 shares of the company's stock valued at $1,769,000 after acquiring an additional 133,757 shares in the last quarter. American Century Companies Inc. raised its holdings in shares of Nuvation Bio by 18.3% in the first quarter. American Century Companies Inc. now owns 486,535 shares of the company's stock worth $856,000 after acquiring an additional 75,362 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Nuvation Bio in the first quarter valued at $799,000. Invesco Ltd. lifted its position in shares of Nuvation Bio by 11.3% in the first quarter. Invesco Ltd. now owns 367,772 shares of the company's stock valued at $647,000 after acquiring an additional 37,384 shares in the last quarter. Finally, XTX Topco Ltd boosted its stake in shares of Nuvation Bio by 424.9% during the first quarter. XTX Topco Ltd now owns 55,564 shares of the company's stock valued at $98,000 after acquiring an additional 44,979 shares during the last quarter. Hedge funds and other institutional investors own 61.67% of the company's stock.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.